We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
CRL

Price
170.44
Stock movement up
+2.80 (1.67%)
Company name
Charles River Laboratories
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Diagnostics & Research
Markedsværdi
8.39B
Ent værdi
12.24B
Pris/omsætning
2.08
Pris/bog
2.43
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-
Efterfølgende P/E
-
Fremtidig P/E
15.64
PEG
-
EPS-vekst
-47.65%
1 års afkast
-9.29%
3 års afkast
-
5 års afkast
-
10 års afkast
-
Senest opdateret: 2025-11-24

UDBYTTE

CRL betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E-
Pris til OCF11.19
Pris til FCF15.43
Pris til EBITDA16.24
EV i forhold til EBITDA23.71

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning2.08
Pris til egenkapital2.43
EV i forhold til salg3.04

iO Charts is a Seeking Alpha partner

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier49.22M
EPS (TTM)-
FCF pr. aktie (TTM)-

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)-
Bruttofortjeneste (TTM)-
Driftsindkomst (TTM)-
Nettoindkomst (TTM)-
EPS (TTM)-
EPS (1 år frem)10.90

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-
Driftsmargin (TTM)-
Fortjenstmargin (TTM)-

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter207.67M
Nettotilgodehavender734.48M
Omsætningsaktiver i alt1.53B
Goodwill2.92B
Immaterielle aktiver571.09M
Ejendomme, anlæg og udstyr0.00
Sum aktiver7.51B
Kreditor169.62M
Kortfristet/nuværende langsigtet gæld2.63B
Summen af kortfristede forpligtelser1.12B
Sum gæld4.06B
Aktionærernes egenkapital3.45B
Materielle nettoaktiver0.00

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)-
Investeringsudgifter (TTM)-
Fri pengestrøm (TTM)-
Udbetalt udbytte (TTM)-

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast-
Afkast af aktiver-
Afkast af investeret kapital-
Kontant afkast af investeret kapital-

iO Charts is a Seeking Alpha partner

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning167.56
Daglig høj171.72
Daglig lav167.45
Daglig volumen569K
Højeste gennem alle tider458.30
1 års analytiker estimat188.47
Beta1.64
EPS (TTM)-
Udbytte pr. aktie0.00
Ex-div dato-
Næste dato for resultatpræsentation-

Nedsidepotensial

Loading...
Nedsidepotensial-data
CRLS&P500
Nuværende prisfald fra top notering-62.81%-2.71%
Højeste prisfald-78.23%-19.00%
Højeste efterår dato11 Apr 20258 Apr 2025
Gennemsnitlig fald fra toppen-64.15%-2.73%
Gennemsnitlig tid til nyt højdepunkt-6 days
Maks. tid til nyt højdepunkt283 days89 days

iO Charts is a Seeking Alpha partner

OPLYSNINGER OM VIRKSOMHEDEN
CRL (Charles River Laboratories) company logo
Markedsværdi
8.39B
Markedsværdi kategori
Mid-cap
Beskrivelse
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. In additionally, It has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. The company was founded in 1947 and is headquartered in Wilmington
Personale
18700
Investor relationer
-
SEC-indsendelser
Adm. direktør
James C. Foster
Land
USA
By
Wilmington
Aktietype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...